Literature DB >> 16806952

Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.

Matthew Maingay1, Marina Romero-Ramos, Manolo Carta, Deniz Kirik.   

Abstract

Parkinson's disease (PD) is characterized by the formation of intracytoplasmic inclusions, which contain alpha-synuclein (alpha-syn) protein. While most profound neurodegeneration is seen in the dopamine (DA) synthesizing neurons located in the ventral midbrain, it is unclear why some DA cell groups are more susceptible than others. In the midbrain, the degeneration of the substantia nigra (SN) DA neurons is severe, whereas the involvement of the ventral tegmental area (VTA) neurons is relatively spared. In the present study, we overexpressed human A53T alpha-syn in the VTA neurons and found that A53T toxicity did not affect their survival. There was, however, a mild functional impairment seen as altered open field locomotor activity. Overexpression of A53T in the SN, on the other hand, led to profound cell loss. These results suggest that the selective susceptibility of nigral DA neurons is at least in part associated with factor(s) involved in handling of alpha-syn that is not shared by the VTA neurons. Secondly, these results highlight the fact that impaired but surviving neurons can have a substantial impact on DA-dependent behavior and should therefore be considered as a critical part of animal models where novel therapeutic interventions are tested.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806952     DOI: 10.1016/j.nbd.2006.04.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  30 in total

Review 1.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

2.  Lack of hypoxia-inducible factor-1 alpha impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling.

Authors:  Javorina Milosevic; Martina Maisel; Florian Wegner; Julia Leuchtenberger; Roland H Wenger; Manfred Gerlach; Alexander Storch; Johannes Schwarz
Journal:  J Neurosci       Date:  2007-01-10       Impact factor: 6.167

3.  Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome.

Authors:  Thorfinn T Riday; Elyse C Dankoski; Michael C Krouse; Eric W Fish; Paul L Walsh; Ji Eun Han; Clyde W Hodge; R Mark Wightman; Benjamin D Philpot; C J Malanga
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

4.  Metabolic connectomics targeting brain pathology in dementia with Lewy bodies.

Authors:  Silvia P Caminiti; Marco Tettamanti; Arianna Sala; Luca Presotto; Sandro Iannaccone; Stefano F Cappa; Giuseppe Magnani; Daniela Perani
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

5.  Differential sensitivity of cranial and limb motor function to nigrostriatal dopamine depletion.

Authors:  Emily K Plowman; Nicholas Maling; Benjamin J Rivera; Krista Larson; Nagheme J Thomas; Stephen C Fowler; Fredric P Manfredsson; Rahul Shrivastav; Jeffrey A Kleim
Journal:  Behav Brain Res       Date:  2012-09-24       Impact factor: 3.332

Review 6.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

Review 7.  Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates.

Authors:  Timothy J Collier; Nicholas M Kanaan; Jeffrey H Kordower
Journal:  Nat Rev Neurosci       Date:  2011-05-18       Impact factor: 34.870

Review 8.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

9.  Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.

Authors:  Nian Xiong; Jinsha Huang; Zhentao Zhang; Zhaowen Zhang; Jing Xiong; Xingyuan Liu; Min Jia; Fang Wang; Chunnuan Chen; Xuebing Cao; Zhihou Liang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

10.  Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.

Authors:  James B Koprich; Tom H Johnston; M Gabriela Reyes; Xuan Sun; Jonathan M Brotchie
Journal:  Mol Neurodegener       Date:  2010-10-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.